383 results about "Pharmacologic therapy" patented technology

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

Provided herein are methods of treating bullous pemphigoid using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of bullous pemphigoid and for use in the manufacture of a medicament for the treatment of bullous pemphigoid are also provided herein.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

A method of using a DNA alkylating agent prodrug compound-containing single drug or using the single drug and other drugs in combination for treatment of p53 gene mutation or defect negative cancer and tumor patients, and a pharmaceutical use. In particular, the DNA alkylating agent prodrug compound is selected from a hypoxia-activated DNA alkylating agent prodrug compound, an AKR1C3-activated DNA alkylating agent prodrug compound, and a β-D-Glucosidase- or β-galactosidase-activated DNA alkylating agent prodrug compound.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a preparation method and application of a granzyme B response near-infrared two-region ratiometric fluorescent probe (DCGA). The DCGA combines the NIR-II dual-emission fluorescence characteristic of rare earth ions with a ratio-type signal response mode, the sensitivity and signal stability of in-vivo fluorescence imaging are greatly improved, ultralow or enhanced F1060nm fluorescence signals are respectively shown before and after interaction with granzyme B (GzmB), F1525nm fluorescence signals are almost kept unchanged, and the DCGA can be used for detecting the in-vivo fluorescence imaging of the granzyme B (GzmB). Therefore, the self-calibration ratio fluorescence imaging GzmB activity change is realized. The DCGA is applied to tumor treatment of immunotherapy drugs, and responders and non-responders of immunotherapy can be distinguished in a non-invasive early stage through ratio fluorescence signals of the DCGA. Therefore, the fluorescent probe can be used as an effective GzmB active NIR-II ratio fluorescence imaging tool, and is expected to provide powerful support for immunotherapy research, precision medicine and personalized diagnosis and treatment.

The invention relates to an application of alvitinib in preparation of an NLRP3 inflammasome inhibitor. The alvetinib is used for preparing a medicament for treating infectious shock, a medicament for treating acute liver injury and a medicament for treating peritonitis. A new choice is provided for prevention or treatment of NLRP3 inflammasome related diseases, the problem of treatment of EGFR mutation lung cancer patients combined with NLRP3 inflammasome related diseases (infectious shock / acute liver injury / acute peritonitis) is solved, tumor progression and inflammatory response are inhibited at the same time through the Aviitinib (third-generation EGFR-TKI), and the NLRP3 inflammasome related diseases are treated through the Aviitinib (third-generation EGFR-TKI). It is suggested that the medicine is preferentially selected by the patients, and the medicine with higher treatment potential is provided for treatment of infectious shock medicines, acute liver injury medicines and acute peritonitis.

The inventive subject matter is directed to inflatable pillows that are useful in the context of non-pharmaceutical therapies. Pillows of the inventive subject matter comprise a hexagonal top surface, a hexagonal bottom surface, and one or more pockets that allow users to place warming / cooling pads beneath the top surface of the pillow. In some embodiments, up to three pockets can be included, where each pocket is accessible along an edge of the top surface. When divided into third, each pocket can be accessible along an edge of the hexagonal outer edge of the top surface such that a user's neck can rest along that edge to improve contact with a warming / cooling pad. Embodiments include an air hub to facilitate inflation and deflation, and a stiff pillow base can be included as well.

The invention relates to the technical field of medical information, in particular to an endocrine patient long-term medication tracking management method and system, and the method comprises the following steps: extracting multiple pieces of key information in a prescription based on the electronic prescription information of a patient, recognizing the taking time and dosage information of multiple medicines, and sending medication reminding information to the patient, by monitoring the opening and closing state of the medicine box, the medicine taking time and quantity are recorded, and reminding and medicine taking monitoring information is generated. According to the method, the opening and closing state of the medicine box is monitored in real time, the taking time and quantity of medicine are recorded, the transparency of medicine treatment and the compliance of a patient are improved, physiological parameters of the patient are collected regularly, time sequence analysis and doctor feedback are matched, the change trend and periodic fluctuation of the illness state of the patient are accurately recognized, and the patient compliance is improved. By analyzing drug use logs of patients and doctors, effects of various drugs are identified, side effects are detected, drug doses and types are helped to be adjusted in time, the risk of adverse drug reactions is effectively reduced, and the treatment effect is improved.

Synergistic drug combinations with small molecule PAC‑1 for the treatment of uveal melanoma or cutaneous melanoma. There are currently no targeted drug therapies for mutations associated with uveal melanoma. As no standard therapy or treatment has improved overall survival, up to 50% of patients eventually develop metastatic disease despite basic radiation or surgical treatment. Drug combinations with PAC 1 allow for the use of lower doses of the compound, resulting in cancer cell death in uveal melanoma. Drug combinations with PAC‑1 and the kinase inhibitor entrectinib have shown synergistic effects against uveal melanoma cell lines. Specifically, PAC‑1 and entrectinib have synergistic effects against wild-type and mutant uveal melanoma cell lines (e.g., GNAQ and GNA11).

Various methods and systems for efficiently providing pharmacogenetic guidelines is disclosed. A drug prescription and a patient genotype can be analyzed to provide a drug therapy recommendation. The analysis can include comparing the patient genotype and the drug name to a drug profile database, a molecular biomarker database, hospital drug reaction records and omics databases, and calculating the patient response to the drug.

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

The invention belongs to the technical field of medicines, and relates to a botulinum toxin A mutant and application thereof. A trinucleotide primer containing NNK at a mutation site is utilized, a site-specific mutagenesis technology is adopted to establish a single-site saturated mutation library and a combined mutation library, and a series of A-type botulinum toxin mutants are obtained through screening; compared with wild type A botulinum toxin, the affinity of the A botulinum toxin mutant and a receptor SV2C is improved; wild Hc / A in the full-length toxin is replaced, the activity and the muscle paralysis causing capacity of the obtained full-length mutant toxin cutting substrate SNAP-25 are improved, the diffusivity is reduced, the lethal dose to mice is remarkably reduced, the safety is improved, and the toxicity of the whole-length mutant toxin cutting substrate SNAP-25 is reduced. The method can be applied to preparation of drugs for treating related diseases which can be treated by wild type toxins through full-length BoNT / A mutant drugs and medical cosmetology related products. Meanwhile, the botulinum toxin A mutant can be used as a drug carrier for targeted nervous system or SV2 receptor drug delivery.

The invention provides a method and device for predicting the treatment effect of methotrexate on psoriasis. According to the method for predicting the therapeutic effect of MTX on psoriasis, the PRS is calculated according to related information of 33 SNP loci in a blood sample of a psoriasis patient, the clinical therapeutic effect of MTX on psoriasis can be well predicted according to the calculation result of the PRS, and clinical doctors can be guided to detect and analyze MTX therapy adopted by part of patients in Chinese population; according to the present invention, the basis is provided for the improvement of the clinical treatment effect of the MTX, the important guiding significance is provided for the subsequent clinical treatment of the psoriasis patient, the improvement of the drug treatment efficiency of the psoriasis patient is easily achieved, and the prediction result of the treatment effect of the MTX on the psoriasis is accurate by simultaneously incorporating the related information of the 33 SNP loci so as to provide the basis for the clinical treatment effect of the MTX; and clinical doctors can be guided to formulate suitable MTX treatment intervention schemes according to individual differences of different patients.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

Compositions, systems, and methods for and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve selection of a subject that is naïve for at least one standard-of-care chemotherapeutic drug (such as, but not limited to, a fibrotic-inducing chemotherapeutic agent), followed by application to the selected subject of an alternating electric field. The method may further include concurrent administration of at least one chemotherapeutic agent to the subject.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

The invention discloses an application of nicotinamide adenine dinucleotide in preparation of a medicine for treating keloid, and by researching the pathophysiological mechanism of keloid, it is found that mechanical related fibroblasts of keloid patients have metabolic reprogramming changes. Fibroblast populations which are mainly pathogenic to keloid have metabolic reprogramming caused by mitochondrial dysfunction, especially glycolysis level enhancement in cells and lactic acid accumulation. The medicine, namely NAD +, capable of regulating and controlling keloid fibroblast glycolysis and mitochondrial metabolism is found and verified through cell and animal experiments, and NAD + inhibits development of keloid by improving mitochondrial dysfunction, reducing lactic acid accumulation and inhibiting fibroblast migration and collagen synthesis. According to the invention, NAD +, which is a common medicine with good safety, is applied to keloid for the first time, and the scheme has small toxic and side effects and also has positive effects on oxidation resistance, aging resistance and cancer resistance, so that a new scheme is provided for treating keloid by medicines.

The present disclosure relates to a method for treating certain tumors or cancers, e.g., plexiform neurofibroma (PN), plexiform neurofibroma associated with neurofibromatosis type 1 (NF1-PN), by administering mirdametinib or a pharma- ceutical acceptable salt thereof to a patient in need thereof, e.g., by certain administration schemes.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The present invention relates to an anti-IL4R antibody. Specifically, provided is an antibody or an antigen-binding fragment thereof capable of specifically binding to IL4R, wherein the antibody or the antigen-binding fragment thereof can specifically bind to IL4R with high affinity, and can be used as a drug to treat diseases related to IL4R.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

A treatment method, wherein a drug which contains an AKR1C3 enzyme-activated or hypoxia-activated anti-cancer prodrug compound, or a salt, ester, solvate or isotopic isomer thereof, is used alone or in combination with other drugs to treat a cancer patient with a negative P53 gene mutation and a positive KRAS gene mutation, or to treat a cancer patient with a negative P53 gene mutation and a positive BRCA gene mutation, or to treat a cancer patient with a positive KRAS gene mutation and a positive BRCA gene mutation, or to treat a cancer patient with a negative P53 gene mutation, a positive KRAS gene mutation and a positive BRCA gene mutation.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

The invention provides application of a CHD1L detection reagent in preparation of a drug-resistant breast cancer screening kit, and belongs to the field of biological medicine. Researches find that when the CHD1L gene expression level in cancer tissues of a breast cancer patient is high, the breast cancer patient is prone to drug resistance to paclitaxel drugs, and the treatment effect of the paclitaxel drugs is poor. The reagent for detecting the CHD1L gene expression level is used for preparing the drug-resistant breast cancer screening kit, can be used for auxiliary diagnosis of clinical breast cancer types, provides an effective basis for related treatment measures or decisions of patients, and has a good clinical application prospect.

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.